Fiduciary Trust Co Raises Position in Zoetis Inc. (NYSE:ZTS)

Fiduciary Trust Co raised its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 6.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 56,192 shares of the company's stock after purchasing an additional 3,545 shares during the quarter. Fiduciary Trust Co's holdings in Zoetis were worth $10,979,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the company. Darwin Wealth Management LLC acquired a new stake in Zoetis during the 3rd quarter worth approximately $31,000. First Personal Financial Services bought a new position in shares of Zoetis during the third quarter valued at $33,000. Capital Performance Advisors LLP acquired a new position in shares of Zoetis during the third quarter worth $33,000. Quarry LP grew its stake in shares of Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company's stock worth $36,000 after purchasing an additional 153 shares during the last quarter. Finally, LRI Investments LLC acquired a new stake in Zoetis in the first quarter valued at $43,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Up 0.6 %

NYSE:ZTS traded up $1.04 during trading hours on Thursday, reaching $176.74. The company had a trading volume of 2,315,768 shares, compared to its average volume of 2,968,865. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The firm has a market cap of $79.74 billion, a price-to-earnings ratio of 33.22, a P/E/G ratio of 2.70 and a beta of 0.90. The business's 50-day simple moving average is $184.51 and its two-hundred day simple moving average is $180.81.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating analysts' consensus estimates of $1.46 by $0.12. The business had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm's revenue was up 11.6% compared to the same quarter last year. During the same period in the previous year, the company posted $1.36 EPS. On average, equities analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be given a $0.432 dividend. This represents a $1.73 annualized dividend and a yield of 0.98%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis's payout ratio is currently 32.52%.

Analyst Ratings Changes

Several research analysts have commented on the company. Argus raised Zoetis to a "strong-buy" rating in a report on Friday, August 9th. Stifel Nicolaus upped their target price on Zoetis from $200.00 to $210.00 and gave the company a "buy" rating in a report on Wednesday, September 18th. JPMorgan Chase & Co. raised their price target on shares of Zoetis from $225.00 to $230.00 and gave the stock an "overweight" rating in a report on Friday, October 11th. BTIG Research boosted their price target on shares of Zoetis from $220.00 to $225.00 and gave the stock a "buy" rating in a research report on Monday, August 12th. Finally, Piper Sandler increased their price objective on shares of Zoetis from $195.00 to $210.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 14th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.